Torrent Pharmaceuticals announced robust financial results for the first quarter of FY27, reporting a 55% year-over-year increase in revenue to ₹4,921 crore. The company also saw a substantial rise in operating EBITDA, which grew by 61% to ₹1,664 crore. Net profit after tax stood at ₹566 crore for the quarter ended June 30, 2026.
Torrent Pharma Reports Strong Q1 FY27 Performance
Torrent Pharmaceuticals Limited today announced its financial results for the first quarter of the financial year 2027 (Q1 FY27), ending on June 30, 2026. The company has delivered a record high organic growth, driven by strong performance across its business segments.
Key Financial Highlights (Consolidated)
The consolidated financial summary for Q1 FY27 showcases significant year-over-year growth:
- Revenues reached ₹4,921 crore, an increase of 55% compared to ₹3,178 crore in Q1 FY26.
- Gross profit grew by 56% to ₹3,758 crore, with a Gross Margin of 76.4%.
- Operating EBITDA* surged by 61% to ₹1,664 crore, compared to ₹1,032 crore in the previous year. The Operating EBITDA margin was 33.8%.
- Net Profit After Tax (PAT) was reported at ₹566 crore, an increase of 3% year-over-year.
- Exceptional items amounted to ₹21 crore for the quarter.
*Operating EBITDA is before exceptional items.
Geographical Performance Highlights
The company’s performance was bolstered by strong growth in key markets:
India Business
India revenues stood at ₹2,157 crore, a 19% increase, outpacing the IPM growth of 12%. Torrent Pharma has achieved the 1st rank in the IPM cardiac market and continues to show strong performance in this segment. Gx Semaglutide recorded a market share of 36% in Q1 FY27.
Brazil Business
Revenues in Brazil increased by 27% to ₹277 crore. The company experienced a 21% growth against a market growth of 5%, supported by its top brands and recent launches.
United States Business
US revenues grew by 36% to ₹418 crore, driven by successful new launches achieving targeted market share.
Germany Business
Germany revenues saw a 3% increase to ₹318 crore, though constant currency revenues were down by 9%. Growth was impacted by supply disruptions and lower tender offtake.
JB Business Performance
The JB Business reported revenues of ₹1,201 crore, a 10% increase year-over-year. Operating EBITDA for the JB business grew by 34% to ₹424 crore.
Amalgamation with J.B. Chemicals & Pharmaceuticals Limited
The document also detailed the Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) with Torrent Pharmaceuticals. The amalgamation became effective on July 8, 2026, with an appointed date of January 21, 2026. The financial results reflect the impact of this amalgamation, with comparative figures restated accordingly.
Source: BSE
